₹ 568.85
Key Takeaways
Risk factor
Low price volatility
Profitability factor
Strong margins and returns
About
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India, North America, Europe, Latin America, Africa, the Middle East, and internationally. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers various FDs, such as...
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is reasonably priced on P/E, of fair value on EV/EBITD.
Target Price
The average target price of GRANULES.NS is 587 and suggests 3% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommenda
